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SUMMARY 1 
A panel of nine experts applied multi-criteria decision analysis (MCDA) to determine the relative 2 
overall harm to users and harms to others of street heroin (injected and smoked) and eleven non-3 
medically used prescription opioids. The experts assessed harm scores for each of the 13 opioids 4 
on each of 20 harm criteria, weighted the criteria and explored the resulting weighted harm scores 5 
for each opioid. 6 
Both forms of heroin scored very high: overall harm score of 99 for injected heroin and 72 for 7 
smoked heroin on a scale of 0-100. The main feature that distinguishes both forms of street 8 
heroin use is that their harm to others is more than five times that of the other eleven opioids. The 9 
overall harm score of fentanyl (including injection of fentanyl extracted from patches) and 10 
diamorphine (medically prescribed form of heroin) was 54 and 51, respectively, whereas that of 11 
orally used opioids ranged from 32 (pethidine) to 11 (codeine-containing pharmaceuticals). 12 
Injected street heroin, fentanyl and diamorphine emerged as most harmful to users, with the latter 13 
two very low in harm to others. Pethidine, methadone, morphine and oxycodone are also low in 14 
harm to others, while moderate in harm to users. 15 
We conclude that the overall harms of non-medically used prescription opioids are less than half 16 
that of injected street heroin. These data may give a basis for precautionary regulatory measures 17 
that should be considered if the rising trend in non-medical use of prescription opioids were to 18 
become evident in the UK.  19 
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INTRODUCTION 1 
Prescription opioids are non-medically used for a variety of reasons, mostly because they give 2 
benefits ranging from pain relief to euphoria. For non-medical use a variety of definitions are 3 
used in the studies described in literature. Here, after discussion, non-medical use was defined as 4 
“taking too much and/or too long” for whatever reason, where too much and too long are defined 5 
as discordant with the usual medical use of the drug. This definition encompasses use not 6 
prescribed, or beyond that prescribed, as well as use with no medical sanction or intention. The 7 
type of opioid use that was evaluated by the experts in the current study was ‘non-medical or 8 
illicit use’ of prescription opioids. 9 
Over the past two decades in the U.S. and to a lesser extent in Canada, the use of opioid 10 
analgesics, especially oxycodone (OxyContin), increased 10 to 14-fold (Manchikanti et al., 11 
2012). This increase followed a liberalization of the law in prescribing opioid analgesics by the 12 
Federation of State Medical Boards, which encouraged doctors to be more proactive in 13 
identifying and treating chronic pain (FSMB, 1998). As a consequence, in the U.S., the number 14 
of opioid prescriptions delivered by pharmacies between 1991 and 2011 increased from 76 to 219 15 
million (Volkow, 2014). Furthermore, between 1999 and 2008, the four-fold increase in the 16 
prescribing of opioid analgesics was paralleled by a four-fold increase in both the number of 17 
opioid dependent people (from 2.2% to 9.8%) and the number of fatal opioid related overdoses 18 
(CDC, 2011). In the U.S. in 2012, 75% of all fatal incidents with pharmaceutical products were 19 
related to opioids (Jones et al., 2013) and 420,000 visits to the emergency departments were 20 
opioid related (SAMHSA, 2013). Therefore, the increased misuse of opioid analgesics and the 21 
clear increase in opioid-related morbidity and mortality in the U.S. was labelled by the CDC as 22 
one of the top five health threats for 2014 (CDC, 2013).  23 
In the past two decades, the use of opioid analgesics also significantly increased in Europe 24 
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(DCAMC, 2012, Ruscitto et al., 2014, Zin et al., 2014, Schubert et al., 2013, Bandieri et al., 1 
2009, Garcia del et al., 2008, Poulsen et al., 2013, Fredheim et al., 2010, Hawton et al., 2012, 2 
NHS, 2011), but it is unlikely that in the UK and elsewhere in Europe the non-medical use of 3 
prescription opioids will become as prevalent as in the U.S. (Fischer et al., 2014, Weisberg et al., 4 
2014). In the U.S. opioids are widely available as they are often given by family and friends or 5 
can be obtained by "doctor shopping" or purchased from semi-legal and illegal pain clinics. For a 6 
review about the misuse of prescription opioids, see van Amsterdam and van den Brink (2015). 7 
In comparison, access to more potent opioid medications for pain relief in the UK seems to be 8 
limited due to the stricter legislation and regulation and the efficient control of both the 9 
prescription and the delivery of opioid analgesics using electronic patient records. However, it 10 
has been shown that 30% of UK patients with opiate substitution prescriptions sold, gave away or 11 
swapped their medication (Dale-Perera et al., 2012), explaining the relatively high misuse of 12 
diverted opioid substitution medication amongst drug using populations in England and Scotland, 13 
mainly by out-of-treatment opioid users (Stöver, 2012), compared to other drug using populations 14 
in European counties (Dale-Perera et al., 2012). The increased use of opioid analgesics in Europe 15 
was not accompanied by an increase in the misuse of these drugs or an increased number of fatal 16 
incidents. While in the U.S. the use of opioids between 1999 and 2008 (in morphine equivalents 17 
per person per year) increased from 350 to 700 and the number of drug deaths doubled from 6 to 18 
12 per 100,000, the use of opioids in Britain increased from 100 to 300, but the number of drug 19 
deaths remained stable at 6 per 100,000 (Weisberg et al., 2014). These data suggest that in the 20 
U.S. the widespread use of opioid analgesics has increased the prevalence of opioid abuse, 21 
whereas in the UK misuse of prescribed opioids is predominantly misuse of formulations 22 
prescribed as heroin substitutes, which tend to be less risky than misuse of heroin and other street 23 
opiates. 24 
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If the non-medical use of prescription opioids were to increase in Europe, this would be from a 1 
relatively high baseline, so future precautionary regulatory responses may be needed. Therefore, 2 
the relative overall harm of eleven non-medically used opioid analgesics was evaluated, using 3 
street heroin as a reference. This is important as the problems in the U.S. and Canada occur 4 
mainly with three specific prescription opioids: hydromorphone, oxycodone and fentanyl (Fischer 5 
et al., 2014).  6 
 7 
METHOD 8 
Nine experts with expertise in either drug addiction or pain treatment (8 from the UK, 1 from the 9 
Netherlands and all listed as authors of this paper) were invited to take part in this assessment by 10 
DrugScience.org.uk (formerly known as the Independent Scientific Committee on Drugs or 11 
ISCD). The experts’ specialisms included addiction, substance abuse, addiction psychiatry, health 12 
psychology, pharmacology, psychopharmacology, toxicology and veterinary science.  13 
The experts attended a two-day facilitated workshop (Phillips, 2007) to assess the actual and 14 
potential harms related to the ‘non-medical or illicit use’ of eleven prescription opioids for 15 
whatever reason they were used. In addition, injected and smoked street heroin were evaluated 16 
for comparison. Illicit or non-medical use of opioids can create harms to users and harms to 17 
others, a distinction that had been used before in the assessment of the overall harm of alcohol, 18 
tobacco and a number of illicit drugs (van Amsterdam et al., 2010, van Amsterdam et al., 2015, 19 
Nutt et al., 2010). 20 
All experts were guided by the facilitator (LP) through the methodology and the principles of 21 
multi-criteria decision analysis (MCDA) as they constructed a model of overall harm (Nutt et al., 22 
2010, Nutt et al., 2014). The 16 criteria used in these studies were taken from the Nutt et al. 2010 23 
study [25] as a starting point. However, the criteria ‘Specific impairment in mental functioning’, 24 
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‘Injury’, ‘Environmental damage’ and ‘International damage’ were very slightly modified to 1 
reflect the narrower scope of the current study. In addition, four new criteria were used covering 2 
the concerns of the expert group related specifically to opioids: ‘drug interactions’: extent to 3 
which this drug could interact with other drugs to increase harm; ‘tolerance’: the risk of overdose 4 
death following loss of tolerance after abstinence or greatly reduced use; ‘availability’: extent and 5 
ease of obtaining a supply; ‘altered prescribing’: inhibition of clinically indicated prescribing due 6 
to concerns regarding the potential for dependence and diversion. The 20 criteria were clustered 7 
under five subheadings covering the following domains: (1) physical, (2) psychological and (3) 8 
social harm to users, and (4) physical and (5) social harm to others (cf. Fig. 1). Each criterion was 9 
carefully explained to the experts by the facilitator which enabled them to evaluate all opioids in 10 
a consistent and meaningful way.  11 
The following 13 opioids were selected for ranking: injected street heroin, smoked heroin, 12 
transdermal fentanyl (including injected fentanyl extracted from patches), pharmaceutical grade 13 
injectable diamorphine usually prescribed for treatment of heroin dependence pethidine, 14 
methadone, morphine, oxycodone, buprenorphine, tramadol, suboxone (buprenorphine + 15 
naloxone), codeine + dihydrocodeine, and compound codeine products. The routes of 16 
administration considered included oral, snorting, chewing (patches) or i.v. injection. 17 
 18 
Scoring principles 19 
The experts scored the criteria directly one by one following the harm tree shown in Figure 1 20 
from top to bottom. The facilitator ensured that all viewpoints were aired, judgements were 21 
backed with data if available, and bias was minimised by selecting the most harmful drug for 22 
each effect and making assessments (e.g., by applying the ‘think, speak, debate’ sequence of the 23 
nominal group technique (Gustafson et al., 1973), which prevents each participant from 24 
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anchoring their judgement on that of the first person to speak). Per criterion each expert had first 1 
to consider his/her score together with an argument before sharing the score with the group. After 2 
sharing the scores and their subsequent justifications the final integral score of the expert group 3 
was obtained via consensus. This procedure applied both to harm scores as well as to the rating of 4 
weighting factors. In making their judgements, participants frequently referred to published data, 5 
which were discussed for their representativeness and quality, and debated in light of experience 6 
with users. This enabled the group to construct consensus harm scores that represented the 7 
participants’ collective judgement in light of the evidence and available experience. Occasional 8 
marked disagreements were noted and tested in sensitivity analyses. This scoring process is 9 
specifically designed to minimise bias (Phillips, 2007). 10 
 11 
Scoring procedure 12 
First, the most harmful opioid on a given criterion was identified and agreed by the group. That 13 
opioid (and any others deemed equally most harmful) was given a harm value of 100, with zero 14 
representing no harm; these two points established a ratio scale. Second, each of the remaining 15 
opioids was assigned a harm value as a percentage representing the ratio of judged harm 16 
compared to the most harmful opioid on the criterion (e.g., an opioid judged to be half as harmful 17 
as the most harmful one was given a harm value of 50). 18 
 19 
Weighting the effect scales 20 
Weight factors were given to each harm criterion to weight the relative importance of each harm 21 
criterion to the overall harm of the 13 opioids. This was accomplished by assessing a separate 22 
swing-weight (scale 0-100) for each of the criteria, the swing from no harm at all to the most 23 
harmful drug on a given criterion. After the weights have been normalised so they sum to 100 24 
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over all 20 criteria (which preserves their original ratio to one another), the weights are known as 1 
‘cumulative weights’ and represent the difference in judged harm between no harm and the most 2 
harmful opioid on each effect. The harm score for an opioid on a given effect scale is multiplied 3 
by the cumulative weight for the scale, and those products are summed over the 20 criteria, 4 
giving an overall weighted preference score for each opioid.  5 
 6 
Sensitivity analysis 7 
Finally, the group explored the results and conducted sensitivity analyses to determine the extent 8 
to which uncertainty in the data and differences of opinion could change the overall ordering of 9 
opioids. 10 
 11 
RESULTS 12 
Ranking the opioids 13 
Table 1 shows the cumulative weights associated with each criterion. Note that 16 of the 20 14 
criteria each contribute 3% to 9% of the total weight with the highest values for Drug specific 15 
mortality, Tolerance, Crime and Economic costs. Drug related impairment of functioning, 16 
availability, altered prescribing and environmental damage together contribute only 3.6%. 17 
Considering the recent widespread misuse of prescription opioids in Canada and the U.S., it 18 
should be highlighted here that the availability of opioids was scored 100 for codeine compounds 19 
(OTC; freely available in pharmacies), 90 for injected and smoked heroin and 50 for methadone. 20 
The remaining opioids were scored below 30. As stated above, data from England and Scotland 21 
indicate that illicit methadone and buprenorphine diverted from prescriptions are readily available 22 
in the illegal drug supply system. Moreover, the weight factor for availability was only 0.9. 23 
A graphical presentation of the individual contributions of weighted scores of the 13 opioids for 24 
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the 20 effects (260 scores) is complex and not legible in a grey-scale display so only the overall 1 
score of harm to others and harm to users is presented in Figure 2. Note that the sum of the 2 
cumulative weights for the 11 harm scales for users is 60%, and is 40% for the 9 harm scales for 3 
others. 4 
The ranking of the opioids in Figure 2 clearly shows that injected street heroin and smoked street 5 
heroin are the most harmful of these 13 opioids. Injected heroin was scored 100, most harmful, 6 
on 11 of the 20 harm criteria, while although smoked heroin scored 100 on only four harm 7 
criteria, it scored 70 or above on 10 additional criteria. The main feature that distinguishes both 8 
heroin opioids from all the other opioids is that street heroin is over five times more harmful to 9 
others. The other 11 opioids are all much lower in their harm to others (value below 6.6 on the 10 
scale from 0 to 100), while varying in their harms to users. 11 
Injected heroin, fentanyl + and diamorphine emerged as most harmful to users, mainly because 12 
these three opioids are dosed intravenously which has a high risk of harm from overdosing during 13 
non-medically supervised use. Similarly, smoked heroin is considered less harmful for the user 14 
than injected heroin, because with smoking the dose can be titrated and tends to be limited by the 15 
user’s degree of intoxication. Pethidine, methadone, morphine and oxycodone were ranked as 16 
lower in harm to others, while moderate in their harm to users. The remaining five opioids are 17 
less potent opioid agonists (buprenorphine, tramadol, suboxone, codeine comb. and codeine) that 18 
are all lower in harm to users and in harm to others. The small 1-point difference between 19 
compound codeine products and codeine resulted from markedly different characteristics: 20 
compound codeine was considered as more harmful on drug specific damage to the users (due to 21 
the potential for paracetamol overdose), whereas codeine was more harmful mainly because of its 22 
higher tolerance. 23 
Plotting the harm to users against the harm to others (Figure 3) clearly indicates that smoked and 24 
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injected heroin were scored as the most harmful opioids for others (appearing in the right upper 1 
quadrant) while fentanyl + and diamorphine are equally harmful for users, but much less harmful 2 
to others (right lower quadrant).  3 
 4 
Sensitivity analyses 5 
Because street heroin is the most harmful opioid on harm to the user and on harm to others, it 6 
maintains its position as the overall most harmful drug whatever the weight on users or others. 7 
All other opioids became more harmful overall as the weight on the harm to users was increased, 8 
whereas only smoked heroin became less harmful with more weight on the harm to users. It 9 
appeared that unrealistically large changes for a few of the harm criteria were required to make a 10 
serious difference, implying that the model is very robust to differences in the judgements about 11 
the weights on the individual harm criteria. However, a few opioids showed substantial changes 12 
in their ranking when the weights on certain criteria were increased. Compound codeine was 13 
particularly susceptible: increasing the weight on ‘drug specific damage’ or on ‘availability’ 14 
caused compound codeine to move up the rank order: the more weight, the higher the rank. 15 
Diamorphine was especially sensitive to the weight on ‘altered prescribing’; increasing the 16 
weight on that harm to a little more than 30% moved diamorphine to the most harmful position 17 
after injected street heroin. 18 
Once the final ranking was obtained and presented, the participants found the overall results to be 19 
a reasonable representation of overall harm; they realised that testing their few early differences 20 
in judgements would not reveal any substantial change in the overall ordering of the 13 opioids. 21 
 22 
DISCUSSION 23 
The main finding of this study is that the overall harm of a variety of non-medically used 24 
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prescription opioids is less than half the overall harm of injected street heroin. For the most part 1 
this difference emerges from the high harm that is elicited by the use of (injected and smoked) 2 
street heroin. For pethidine, diamorphine and fentanyl+ the harm for the user was at least half as 3 
high as injected heroin’s user harm, which shows a considerable risk if used non-medically. At 4 
the other end of the spectrum, codeine preparations and suboxone (a buprenorphine-naloxone 5 
combination) had the lowest overall harm scores. 6 
The relative overall harm of a variety of licit and illicit recreational drugs for the user and for 7 
others was previously assessed in two independent studies using a similar methodology (Nutt et 8 
al., 2010, van Amsterdam et al., 2015). The set of substances in these studies held three drugs in 9 
common with the present study i.e. heroin, methadone and buprenorphine. Pearson correlation 10 
coefficients of 0.90 to 0.98 for input scores on each of the 16 criteria these two studies and the 11 
present study held in common were calculated, providing substantial support for the reliability 12 
and validity of scores generated by the groups, at least for the three opioids considered in each 13 
analysis. Apparently, the group deliberation and discourse provided scores for these three 14 
substances that were consistent and replicable.  15 
Process validity derives from the soundness of the social process, i.e. decision conferencing. 16 
Research on decision conferences (Schilling et al., 2007, Chun, 1992, McCartt and Rohrbaugh, 17 
1995, McCartt and Rohrbaugh, 1989) and group workshops (Franco and Montibeller, 2015, 18 
Phillips, 2011, Schilling et al., 2007) has identified four features that contribute to validity: 19 
competence of the experts (Shanteau, 1992), diversity of perspectives in the group (Shanteau, 20 
2001), impartial facilitation by a facilitator who guides the process but does not contribute to 21 
content (Phillips, 2007), and development on-the-spot of a model that is based on sound theory 22 
(Regan-Cirincione, 1994), in this case, decision theory (Dodgson et al., 2000, Keeney and Raiffa, 23 
1976). All of these factors were applied, as far as was practically possible, in designing and 24 
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conducting the decision conference that was used for this study.  1 
It should be noted here that while the magnitude of the harm for the different criteria can be 2 
informed by data, the magnitude of weighting factors is not based on data and remains 3 
exclusively a matter of judgement. On the other hand, however, the comparison of unweighted 4 
overall harm scores can be misleading and one should remain careful not to over-interpret the 5 
findings. Finally, we would like to mention that the applied MCDA approach has been criticised 6 
(Caulkins et al., 2011). Caulkins et al. (2011) proposed an alternative approach that also included 7 
the benefits of the different substances. However, Caulkins’ approach probably makes it even 8 
more difficult to establish a one-number estimate for the (net) harm of substances and the validity 9 
of his approach is unknown. Moreover, it should be noted that in contrast to the risk-benefit 10 
evaluation of pharmaceutical compounds, the score in drug evaluation is only meant as a measure 11 
of harm because in recreational drug use there is no illness and no potential clinical benefit. 12 
The present assessment corroborated the low availability of prescription opioids in the UK 13 
(except for codeine), considering the low scores on the criterion ‘availability’. Secondly, both in 14 
the U.S. and the UK opioid painkillers and heroin share a common market (Weisberg et al., 2014; 15 
Inciardi et al., 2009), but the price of heroin in the U.S. is about 7-8 times higher compared with 16 
the UK, which may have prevented or at least retarded the development of an illegal market and 17 
misuse of opioid analgesics (Weisberg et al., 2014). For these reasons it would be of interest to 18 
repeat this MCDA harm assessment in the USA. 19 
This analysis shows there are very significant differences in the relative harms of the various non-20 
medically used opioids. Street heroin whether injected or smoked was ranked as the most harmful 21 
opioid in the UK today followed by non-medically used prescription opioids such as diamorphine 22 
and fentanyl patches. Unexpectedly, oxycodone turned out to be only moderately harmful. This 23 
contrasts with the extensive abuse of this specific prescription opioid in the U.S. and Canada. The 24 
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explanation could be that oxycodone was “aggressively marketed and highly promoted” in North 1 
America (Van Zee, 2009) leading to a more than 20-fold increase in sales in four years, more 2 
than all other prescription opioids and much more marketing than is allowed for any opioid in the 3 
UK. This illustrates that drug harms are not independent of prevalence of use. The current 4 
findings have implications for the provision of pain treatment and could provide a basis for 5 
precautionary regulatory measures should these become necessary due to a future increase in 6 
non-medical use of prescription opioids. However, such measures should be proportionate and 7 
not restrict or obstruct the treatment of chronic pain and heroin dependence.  8 
The group finally agreed that it would be of value to include real or perceived benefits of drugs in 9 
a future MCDA exercise as it was important to recognise drivers for illicit drug taking including 10 
pleasure, pain relief or escape from negative cognitive states. However, it was agreed this would 11 
double the length of the exercise and should be the focus of a future decision making exercise 12 
provided that funding could be found. 13 
 14 
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Experts: James Bell, Owen Bowden-Jones, Annette Dale-Perera, Richard Hammersley, Graeme 16 
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Legends to figures 1 
 2 
Figure 1. The 20 harm criteria for prescription opioids. See Nutt et al. 2010 for details. 3 
 4 
Figure 2. The opioids ranked by their overall weighted harm scores, with the stacked bar 5 
graphs showing the contribution to the overall score of harm to others and harm to users with a 6 
cumulative weight of 40.0 and 60.0, respectively. Injected heroin: street heroin taken 7 
intravenously; Smoked heroin: smoked street heroin; Fentanyl +: non-medical use of patches, 8 
including injection of fentanyl extracted from patches; Codeine Comb.: compound codeine 9 
products. 10 
 11 
Figure 3. Harms to Others versus Harms to User relative to injected heroin. 1: Injected 12 
heroin; 2: Smoked heroin; 3: Fentanyl+; 4: Diamorphine and 5: Pethidine.  13 
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Table 1. Cumulative weight of the 20 criteria 
Name Cumulative weight 
Drug specific mortality 8.8 
Drug related mortality 7.5 
Drug specific damage 5.7 
Drug related damage 5.7 
Drug interactions 5.7 
Tolerance 8.8 
Dependence 5.7 
Drug specific impairment of mental functioning 4.2 
Drug related impairment of mental functioning 1.4 
Loss of tangibles 3.0 
Loss of relationships 3.5 
Injury 5.3 
Availability 0.9 
Crime 8.8 
Environmental damage 0.4 
Family adversities 7.9 
International damage 3.5 
Economic cost 8.8 
Community 3.5 
Altered prescribing 0.9 
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Figure 1 The 20 harm criteria for prescription opioids. See Nutt et al. 2010 for details. 
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Figure 2: The opioids ranked by their overall weighted harm scores, with the stacked 
bar graphs showing the contribution to the overall score of harm to others and harm to 
users with a cumulative weight of 40.0 and 60.0, respectively. Injected heroin: street 
heroin taken intravenously; Smoked heroin: smoked street heroin; Fentanyl +: non-
medical use of patches, including injection of fentanyl extracted from patches; Codeine 
Comb.: compound codeine products. 
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Fig 3. Harms to Others versus Harms to User relative to injected heroin. 1: Injected 
heroin; 2: Smoked heroin; 3: Fentanyl+; 4: Diamorphine and 5: Pethidine. 
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Highlights 
 
• If misused, prescription opioids may be harmful. 
• The overall harm of injected and smoked street heroin is considerably more harmful than 
the non-medical use of the most potent prescription opioids fentanyl and diamorphine. 
• Precautionary regulatory measures are to be taken if the rising trend in non-medical use of 
prescription opioids were to become evident in the UK. 
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Data imported from the Hiview3 model of the harm of opioids
Assessed Scores
Criteria Weights Normalised weightsInj heroinSmoked heroinF ntanyl +DiamorphinePethidineMethadoneMorphineOxycodoneBuprenorphineTramadolSuboxoneCodeine Comb.deine
DRUG SPEC MORT 100 0.0879 100 50 100 100 60 50 50 5 20 30 15 10 10
DRUG REL MORT 85 0.0747 100 30 70 10 10 10 10 10 5 10 5 15 7
DRUG SPEC DAMAGE 65 0.0571 100 35 30 20 20 20 20 20 10 10 10 50 10
DRUG REL DAMAGE 65 0.0571 100 35 80 80 80 25 25 25 20 5 20 15 5
TO DRUG INTERACTIONS 65 0.0571 100 70 100 100 65 65 65 65 30 10 30 40 30
USER TOLERANCE 100 0.0879 100 80 100 100 20 40 40 40 10 30 10 5 20
DEPENDENCE 65 0.0571 100 90 100 100 55 55 50 60 35 35 30 15 25
SPEC IMPAIRMENT FUNC 48 0.0422 100 100 100 100 100 50 55 55 10 45 10 15 25
REL IMPAIRMENT FUNC 16 0.0141 100 80 100 100 100 80 50 50 40 30 40 10 30
LOSS OF RELAT 40 0.0351 100 90 100 100 60 60 40 40 60 20 60 5 20
LOSS OF TANGIBLES 34 0.0299 100 70 100 100 80 50 55 55 45 35 45 10 35
INJURY 60 0.0527 100 90 10 40 20 40 20 20 30 10 15 5 5
CRIME 100 0.0879 100 100 1 1 1 15 1 1 10 1 5 1 1
ENVIRONM DAMAGE 5 0.0044 100 5 2 2 2 2 1 1 1 1 1 1 1
FAMILY ADVERSITIES 90 0.0791 100 85 1 2 1 10 5 2 7 5 3 5 5
ECONOMIC COST 100 0.0879 100 80 2 3 2 15 3 2 10 2 2 3 2
INTERNATIONAL DAMAGE 40 0.0351 100 100 0 0 0 0 0 0 0 0 0 0 0
COMMUNITY 40 0.0351 100 100 1 1 1 7 1 1 5 1 2 1 1
AVAILABILITY 10 0.0088 90 90 1 1 1 50 5 1 30 20 10 100 20
ALTERED PRESCRIBING 10 0.0088 0 0 10 100 10 55 30 40 20 20 0 0 5
Totals 1138 1.0000 99 72 54 51 32 31 26 22 17 15 14 12 11
Weighted Scores Injected heroinSm ked heroinF ntanyl +DiamorphinePethidineMethadoneMorphineOxycodoneBuprenorphineTramadolSuboxoneCodeine Comb.deine
DRUG SPEC MORT 8.79 4.39 8.79 8.79 5.27 4.39 4.39 0.44 1.76 2.64 1.32 0.88 0.88
DRUG REL MORT 7.47 2.24 5.23 0.75 0.75 0.75 0.75 0.75 0.37 0.75 0.37 1.12 0.52
DRUG SPEC DAMAGE 5.71 2.00 1.71 1.14 1.14 1.14 1.14 1.14 0.57 0.57 0.57 2.86 0.57
DRUG REL DAMAGE 5.71 2.00 4.57 4.57 4.57 1.43 1.43 1.43 1.14 0.29 1.14 0.86 0.29
DRUG INTERACTIONS 5.71 4.00 5.71 5.71 3.71 3.71 3.71 3.71 1.71 0.57 1.71 2.28 1.71
TOLERANCE 8.79 7.03 8.79 8.79 1.76 3.51 3.51 3.51 0.88 2.64 0.88 0.44 1.76
TO DEPENDENCE 5.71 5.14 5.71 5.71 3.14 3.14 2.86 3.43 2.00 2.00 1.71 0.86 1.43
OTHERS SPEC IMPAIRMENT FUNC 4.22 4.22 4.22 4.22 4.22 2.11 2.32 2.32 0.42 1.90 0.42 0.63 1.05
REL IMPAIRMENT FUNC 1.41 1.12 1.41 1.41 1.41 1.12 0.70 0.70 0.56 0.42 0.56 0.14 0.42
LOSS OF RELAT 3.51 3.16 3.51 3.51 2.11 2.11 1.41 1.41 2.11 0.70 2.11 0.18 0.70
LOSS OF TANGIBLES 2.99 2.09 2.99 2.99 2.39 1.49 1.64 1.64 1.34 1.05 1.34 0.30 1.05
INJURY 5.27 4.75 0.53 2.11 1.05 2.11 1.05 1.05 1.58 0.53 0.79 0.26 0.26
CRIME 8.79 8.79 0.09 0.09 0.09 1.32 0.09 0.09 0.88 0.09 0.44 0.09 0.09
ENVIRONM DAMAGE 0.44 0.02 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
FAMILY ADVERSITIES 7.91 6.72 0.08 0.16 0.08 0.79 0.40 0.16 0.55 0.40 0.24 0.40 0.40
ECONOMIC COST 8.79 7.03 0.18 0.26 0.18 1.32 0.26 0.18 0.88 0.18 0.18 0.26 0.18
INTERNATIONAL DAMAGE 3.51 3.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
COMMUNITY 3.51 3.51 0.04 0.04 0.04 0.25 0.04 0.04 0.18 0.04 0.07 0.04 0.04
AVAILABILITY 0.79 0.79 0.01 0.01 0.01 0.44 0.04 0.01 0.26 0.18 0.09 0.88 0.18
ALTERED PRESCRIBING 0.00 0.00 0.09 0.88 0.09 0.48 0.26 0.35 0.18 0.18 0.00 0.00 0.04
Totals 99 72 54 51 32 31 26 22 17 15 14 12 11
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